

19 May 2021

ASX Announcement

ADALTA GRANTED JAPANESE PATENT PROTECTING AD-214

MELBOURNE Australia, 19 May 2021: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that a key patent relating to the Company's lead program, AD-214, has been granted by the Japan Patent Office (JPO).

Japan Patent Number 6863897 is entitled "CXCR4 binding molecules and methods of use thereof" and has an expiration date of 8 January 2036. This patent includes the composition of AD-214 and its use in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed. The international application for this patent was filed in January 2016 with a priority date of 9 January 2015. Patents are granted on a country-by-country basis and this is the third patent to be granted under this application. The Australian version was granted in 2017 and the US version in 2020. The claims are being pursued in other major markets including the European Union and China.

AdAlta's CEO, Tim Oldham commented,

"This granted patent strengthens AdAlta's patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world. Strong intellectual property protection is essential to our partnering and commercialization strategy."

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
May 2021

Notes to Editors
About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is conducting Phase 1 clinical studies for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and

other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to discover i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immunology drugs.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au